Minoxidil topique 2 % + finastéride oral 5 mg
1 étude, 60 participants · Alopécie androgénétique · Femmes
Chez 60 femmes atteintes d'alopécie androgénétique, un seul essai de fiabilité limitée a opposé le minoxidil topique 2 % associé au finastéride oral 5 mg au même minoxidil associé à la spironolactone orale 100 mg (Sadeghzadeh Bazargan 2024). À 17 semaines, l'association avec le finastéride fait moins bien : aucune patiente nettement améliorée (0 sur 30), 16,7 % sans aucun effet (5 sur 30) et 33,3 % améliorées sur photos jugées à l'aveugle (10 sur 30), des écarts significatifs en faveur de la spironolactone. Un résultat isolé, à confirmer.
Piste explorée
Ce traitement n'a été mesuré que dans une seule étude par critère : il n'existe pas encore assez d'essais pour en tirer une conclusion. Les résultats ci-dessous sont des indices, à lire avec leurs limites.
Les résultats
Critères mesurés dans une seule étude : chaque ligne est un résultat isolé.
Efficacité
- Amélioration marquée0 % (0 sur 30) face à Minoxidil topique 2 % + spironolactone orale 100 mg
Voir la citation
drugs used were ineffective in 2 (6.7%) cases in the minoxidil- spironolactone group and in 5 (16.7%) cases in the minoxidil- finasteride group. In addition, 13 (43.3%) and 16 (53%) cases in the minoxidil- spironolactone and minoxidil- finasteride groups, respec- tively, responded well to the treatment. The effect of treatment was excellent in 8 (56.7%) and 0 (0%) of the mentioned groups, respec- tively, and the mentioned difference was statistically significant (p: 0.01). The response to the treatment in the FPHL was not statisti-
Citation complémentaire (methode)
treatment was 4 months, and follow- up examinations were per- formed 2 and 4 months after the start of treatment. The efficacy of the treatment was evaluated by the following criteria: determina- tion of the degree of hair loss using the Ludwig grade for FPHL and the Norwood– Hamilton grade for MPHL, determination of physician satisfaction by clinical images using the physician global assessment score (no change, little, somewhat, good, and excellent), and deter- mination of patient satisfaction by clinical images according to the density and thickness of the hair shafts and the extent of hair loss (worsening, no change, and improvement).
Sadeghzadeh Bazargan A, Tavana Z, Dehghani A et al.. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. Journal of Cosmetic Dermatology 2024, DOI 10.1111/jocd.15979. Citation sous licence CC-BY.
- Patients améliorés (panel photo en aveugle)33,3 % (10 sur 30) face à Minoxidil topique 2 % + spironolactone orale 100 mg
Voir la citation
(70.0%) and 10 (33.3%) cases, respectively, p: 0.01), Figures 1,2.
Citation complémentaire (methode)
treatment was 4 months, and follow- up examinations were per- formed 2 and 4 months after the start of treatment. The efficacy of the treatment was evaluated by the following criteria: determina- tion of the degree of hair loss using the Ludwig grade for FPHL and the Norwood– Hamilton grade for MPHL, determination of physician satisfaction by clinical images using the physician global assessment score (no change, little, somewhat, good, and excellent), and deter- mination of patient satisfaction by clinical images according to the density and thickness of the hair shafts and the extent of hair loss (worsening, no change, and improvement).
Citation complémentaire (valeur)
spironolactone group than in the minoxidil- finasteride group (21
Sadeghzadeh Bazargan A, Tavana Z, Dehghani A et al.. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. Journal of Cosmetic Dermatology 2024, DOI 10.1111/jocd.15979. Citation sous licence CC-BY.
- Patients sans réponse au traitement16,7 % (5 sur 30) face à Minoxidil topique 2 % + spironolactone orale 100 mg
Voir la citation
drugs used were ineffective in 2 (6.7%) cases in the minoxidil- spironolactone group and in 5 (16.7%) cases in the minoxidil- finasteride group. In addition, 13 (43.3%) and 16 (53%) cases in the minoxidil- spironolactone and minoxidil- finasteride groups, respec- tively, responded well to the treatment. The effect of treatment was excellent in 8 (56.7%) and 0 (0%) of the mentioned groups, respec- tively, and the mentioned difference was statistically significant (p: 0.01). The response to the treatment in the FPHL was not statisti-
Citation complémentaire (methode)
treatment was 4 months, and follow- up examinations were per- formed 2 and 4 months after the start of treatment. The efficacy of the treatment was evaluated by the following criteria: determina- tion of the degree of hair loss using the Ludwig grade for FPHL and the Norwood– Hamilton grade for MPHL, determination of physician satisfaction by clinical images using the physician global assessment score (no change, little, somewhat, good, and excellent), and deter- mination of patient satisfaction by clinical images according to the density and thickness of the hair shafts and the extent of hair loss (worsening, no change, and improvement).
Sadeghzadeh Bazargan A, Tavana Z, Dehghani A et al.. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. Journal of Cosmetic Dermatology 2024, DOI 10.1111/jocd.15979. Citation sous licence CC-BY.
Comparé directement à
Traitements testés contre celui-ci dans un même essai, sur les mêmes patients.
Les études
- Sadeghzadeh 2024 · Essai randomisé, risque de biais élevé. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial